Mark Saldanha, managing director said, “The successful outcome of the cGMP inspection by the US FDA is a testament to our ongoing commitment to product quality and regulatory compliance.”

Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations.

The company’s consolidated net profit dropped 34.3% to Rs 58.31 crore despite of 4.97% jump in revenue from operations to Rs 619.98 crore in Q1 FY26 over Q1 FY25.